Drug Target Review2024-06-04T12:30:07
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2025-07-30T08:00:00
Sponsored by Wuxi Biologics
2025-05-08T09:00:00
Contributor Ning Ren
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2026-03-25T15:00:00
Sponsored by Yokogawa
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2024-02-08T11:07:39
Sponsored by Samplix ApS
Site powered by Webvision Cloud